The Limited Times

Now you can see non-English news...

Omikron consequences for Biontech and Moderna - you should definitely remember this Novavax appointment

2022-01-11T13:15:40.299Z


Omikron consequences for Biontech and Moderna - you should definitely remember this Novavax appointment Created: 01/11/2022, 02:06 PM By: Patricia Huber Despite EU approval, the Novavax share is not yet particularly popular. © MiS / Imago Images With their corona vaccines, shares in the companies Biontech and Moderna have gone through the roof. With the new vaccine Novavax, however, this succe


Omikron consequences for Biontech and Moderna - you should definitely remember this Novavax appointment

Created: 01/11/2022, 02:06 PM

By: Patricia Huber

Despite EU approval, the Novavax share is not yet particularly popular.

© MiS / Imago Images

With their corona vaccines, shares in the companies Biontech and Moderna have gone through the roof.

With the new vaccine Novavax, however, this success is still a long way off.

Gaithersburg / USA - The new Corona * variant Omikron not only has an impact on the pandemic, but also on the vaccine manufacturers and their market value on the stock exchange.

Since milder progressions are often reported with the Omikron variant, hopes of a possible end to the pandemic are increasing.

Corona: Omikron affects vaccine manufacturer stocks

The big producers like Biontech and Moderna therefore suffered losses in the past week.

And that, although the vaccination is still considered the most effective means against infection and a severe course.

The government also repeatedly urges citizens to get vaccinated and boosted.

The new protein-based corona vaccine from Novavax * is particularly interesting for many vaccine skeptics.

Because the process for this vaccine is not as new as it is the case with the mRNA vaccines Biontech or Moderna.

The vaccines against hepatitis B and whooping cough work similarly and have been used for years.

Novavax is not getting very well on the stock market

But Novavax is not doing as well on the stock market as one would expect. In US trading, Novavax shares fell 7.6 percent at the end of the year. One of the reasons for this is that approval in the USA has been delayed for the second time. The company was actually aiming for approval by the end of 2021, reports

onvista.de

. In the EU, the Novavax vaccine was approved before Christmas.

Although B. Riley's analysts continue to recommend buying Novavax shares, investors are still skeptical.

Perhaps one or the other interested party can still be convinced at the JPMorgan HealthCare Conference of the US bank.

As reported by

deraktionaer.de

, Novavax CEO Stanley C. Erck will speak there on January 10th and present the latest developments from his company.

The appointment is eagerly awaited.

(ph) * Merkur.de is an offer from IPPEN.MEDIA.

Source: merkur

All news articles on 2022-01-11

You may like

Trends 24h

News/Politics 2024-03-28T06:04:53.137Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.